Exploration de la fonction dopaminergique dans les dépressions bipolaires et unipolaires

Monreal, José Antonio; Duval, Fabrice; Mokrani, Marie‐Claude; Pinault, Georges-Jean; Mâcher, Jean-Paul

doi:10.1016/j.amp.2005.04.011

Cited by 4 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with several studies ( 5 , 9 , 12 , 40 ) APO induced-PRL suppression is altered in our population of BDs and SADs. The lack of significant difference in the PRL response to APO between SCHs and HCs is also consistent with prior reports ( 5 , 7 , 9 ) but not all ( 41 ).…”

Section: Discussionsupporting

confidence: 94%

“…However, it is also possible that PRLs blunting might be due to functional alteration of lactotrophs cells. This hypothesis is not confirmed by a previous study (40), in which 8 AM and 11 PM PRL responses to TRH stimulation tests were comparable between unipolar (UP) and bipolar depressed patients, while BDs, unlike UPs, exhibited blunted APO-induced PRLs values (12).…”

Section: Apomorphine Testcontrasting

confidence: 68%

See 1 more Smart Citation

Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders

et al. 2020

View full text Add to dashboard Cite

Background: This study aimed to assess hypothalamic-pituitary dopaminergic (DA), noradrenergic (NA), thyroid (HPT), and adrenal (HPA) activity in schizophrenia, in schizoaffective disorder, and in bipolar disorder. Method: We investigated a combined approach of hormone responses to (1) apomorphine (APO), a short-acting DA receptor agonist which decreases prolactin secretion (PRL), and stimulates secretion of growth hormone (GH), adrenocorticotropin (ACTH), and cortisol; (2) clonidine (CLO), an alpha 2-adrenoceptor agonist which stimulates GH secretion; (3) 8 AM and 11 PM protirelin (TRH) which stimulates thyrotropin (TSH) secretion; and (4) dexamethasone which suppresses cortisol secretion, in 13 hospitalized healthy male controls and 39 untreated male inpatients: 13 with DSM-IV paranoid schizophrenia, 13 with DSM-IV schizoaffective disorder (bipolar subtype, depressed at the time of the study), and 13 with DSM-IV bipolar disorder (depressed). Results: Compared to controls, paranoid schizophrenic patients showed (1) lower APOinduced ACTH and cortisol stimulation, and (2) higher post-dexamethasone cortisol values. Compared to controls, schizoaffective and bipolar patients showed (1) lower DDTSH values (i.e., difference between 11 PM and 8 AM TRH-TSH responses), (2) lower APO-induced PRL suppression, (3) lower CLO-induced GH stimulation, and (4) higher post-dexamethasone cortisol values. Conclusions: Although results must be interpreted with caution because of the small sample, this preliminary study suggests that depressed bipolar and schizoaffective patients share common biological dysregulations, distinct from that of paranoid schizophrenic patients. From a pathophysiological viewpoint, paranoid schizophrenic patients can be characterized by hyposensitivity of the hypothalamic DA receptors (possibly resulting from an increase in presynaptic DA release) associated with increased HPA axis activity, while depressed bipolar and schizoaffective patients can be characterized by hyposensitivity of the pituitary TRH and DAD 2 receptors (possibly linked

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Apomorphine Testcontrasting

confidence: 68%

Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders

et al. 2020

View full text Add to dashboard Cite

show abstract

“…68,69 Similar mixed findings exist for the effect of apomorphine on peripheral prolactin concentrations. 67,70 The extent to which DA modulation of an endocrine response reflects DA functioning in the mesocortical, mesolimbic, and nigrostriatal pathways is unknown.…”

Section: Human Genetic and Neurochemical Studiesmentioning

confidence: 99%

The Role of Dopamine in the Pathophysiology of Depression

Dunlop¹,

Nemeroff²

2007

Arch Gen Psychiatry

1,074

714

View full text Add to dashboard Cite

“…Indeed, when depressed patients are classified according to their clinical features, differences in the apomorphine response are observed between subtypes. For example, it has been found, 88 , 92 , 93 but not by all, 90 that apomorphine produces a lesser decrease in serum PRL levels in bipolar patients than in normals and in unipolar patients. On the other hand, unipolar patients with melancholic and psychotic features often show reduced ACTH/cortisol responses especially when hypercortisolism coexists.…”

Section: Neuroendocrine Investigations Of the Da Systemmentioning

confidence: 99%

Neuroendocrine predictors of the evolution of depression

Duval

Mokrani

Ortíz

et al. 2005

Dialogues in Clinical Neuroscience

View full text Add to dashboard Cite

Depression is both clinically and biologically a heterogeneous entity. Despite advances in psychopharmacology, a significant proportion of depressed patients either continue to have residual symptoms or do not respond to antidepressants. It has therefore become essential to determine parameters (or predictors) that would rationalize the therapeutic choice, taking into account not only the clinical features, but also the "biological state," which is a major determinant in the antidepressant response. Such predictors can derive from bioclinical correlates and, in this context, the neuroendocrine strategy appears particularly suited. Numerous studies have investigated neuroendocrine parameters--derived mainly from dynamic challenge tests--in order to (i) determine the predictive profiles of good clinical responders to given antidepressants; (ii) monitor the progression of markers in parallel with the clinical outcome; and (iii) evaluate "in vivo" in humans the mechanisms of action of antidepressant compounds (before, during, and after treatment). This article does not attempt to be exhaustive, but rather uses selected examples to illustrate the usefulness of the investigation of the adrenal and thyroid axes and the assessment of central serotonergic, noradrenergic, and dopaminergic systems by means of neuroendocrine tests. Given methodological constraints, most of these investigations--except for baseline hormone values and the dexamethasone suppression test--cannot be used routinely in psychiatry. Despite these limitations, the neuroendocrine strategy still offers new insights in biology and the treatment of depression. Its possible expansion depends mainly on the development of specific agonists or antagonists for better investigation of the receptors supposedly involved in the pathophysiology of depression. These investigations will help define more homogeneous subgroups from a bioclinical and therapeutic viewpoint.

show abstract

Exploration de la fonction dopaminergique dans les dépressions bipolaires et unipolaires

Cited by 4 publications

References 28 publications

Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders

Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders

The Role of Dopamine in the Pathophysiology of Depression

Neuroendocrine predictors of the evolution of depression

Contact Info

Product

Resources

About